In vitro susceptibility of Cutibacterium acnes to dalbavancin: comparison between gradient test and the agar dilution reference method

Background

Cutibacterium acnes, a human commensal, occasionally causes infections requiring long-term antibiotic treatment, including periprosthetic joint infections. Dalbavancin is a new lipoglycopeptide that allows intermittent dosing because of its exceptionally long half-life. However, data on susceptibility of C. acnes to dalbavancin are lacking, and no EUCAST breakpoints have been defined.